Comparison of Effective Phacoemulsification Times Used in Cataract Surgery between the Veritas Vision System and the Centurion Vision System Authors: Ji Youn Choi, Won Seok Song, Yeo Kyoung Won, Dong Hui Lim Published: 2026 ABSTRACT AbstractPurposeTo compare the effective phacoemulsification time (EPT) used in cataract surgery and postoperative outcomes between the Veritas Vision System and the Centurion Vision System.MethodsA retrospective analysis was conducted on 90 eyes from 82 patients with senile cataracts who underwent cataract extraction by phacoemulsification at Samsung Medical Center from December 2022 to May 2023. According to the Lens Opacities Classification System III grading of nucleus opalescence (NO), eyes with grades 3 to 5 were included, subdivided into moderate (≥NO3, 0.05). Table 2Preoperative characteristics of moderate cataract groupVariableVeritas (n = 26)Centurion (n = 26)p-valueAge (yr)*68.46 ± 9.10 (50–87)65.46 ± 9.45 (40–83)0.249Sex (male : female)†12 : 1411 : 150.780PAM (logMAR)‡0.11 ± 0.13 (0–0.48)0.10 ± 0.21 (0–1.00)0.220BCVA (logMAR)‡0.48 ± 0.66 (0–2.00)0.25 ± 0.26 (0–1.00)0.377ASC (n / total)†12 / 2615 / 260.405CO (n / total)†23 / 2622 / 260.685PSC (n / total)†11 / 268 / 260.388IOP (mmHg)*15.62 ± 2.29 (10–19)15.58 ± 2.75 (10–21)0.957Values are presented as mean ± standard deviation (range) unless otherwise indicated. Values of BCVA are converted to logMAR.PAM = potential acuity meter; BCVA = best-corrected visual acuity; ASC = anterior subcapsular cataract; CO = cortical opacity; PSC = posterior subcapsular cataract; IOP = intraocular pressure.*Independent t-test;†Chi-square;‡Mann-Whitney U-test. Preoperative characteristics of moderate cataract group Values are presented as mean ± standard deviation (range) unless otherwise indicated. Values of BCVA are converted to logMAR. PAM = potential acuity meter; BCVA = best-corrected visual acuity; ASC = anterior subcapsular cataract; CO = cortical opacity; PSC = posterior subcapsular cataract; IOP = intraocular pressure. Independent t-test; Chi-square; Mann-Whitney U-test. Table 3Preoperative characteristics of hard cataract groupCharacteristicVeritas (n = 17)Centurion (n = 21)p-valueAge (yr)*69.53 ± 9.82 (48–87)70.52 ± 8.39 (55–90)0.743Sex (male : female)†5 : 129 : 120.393PAM (logMAR)‡0.28 ± 0.29 (0–1.00)0.13 ± 0.13 (0–0.48)0.055BCVA (logMAR)‡0.54 ± 0.41 (0.10–1.00)0.58 ± 0.62 (0–2.00)0.506ASC (n / total)†4 / 175 / 210.984CO (n / total)†10 / 1714 / 210.618PSC (n / total)†8 / 1711 / 210.744IOP (mmHg)*15.53 ± 2.40 (11–19)15.19 ± 2.38 (10–19)0.676Values are presented as mean ± standard deviation (range) unless otherwise indicated.PAM = potential acuity meter; BCVA = best-corrected visual acuity; ASC = anterior subcapsular cataract; CO = cortical opacity; PSC = posterior subcapsular cataract; IOP = intraocular pressure.*Independent t-test;†Chi-square;‡Mann-Whitney U-test. Preoperative characteristics of hard cataract group Values are presented as mean ± standard deviation (range) unless otherwise indicated. PAM = potential acuity meter; BCVA = best-corrected visual acuity; ASC = anterior subcapsular cataract; CO = cortical opacity; PSC = posterior subcapsular cataract; IOP = intraocular pressure. Independent t-test; Chi-square; Mann-Whitney U-test. Effective phaco time was measured as EPT in the Veritas group and as CDE in the Centurion group. In the moderate cataract group (Table 4), EPT was significantly lower in the Veritas group than in the Centurion group (p = 0.035). There was no significant difference in postoperative BCVA (p = 0.431) and IOP (p = 0.129), and both groups remained within the normal range of IOP. Table 4EPT and postoperative outcomes of moderate cataract groupVariableVeritas (n = 26)Centurion (n = 26)p-valueEPT (%·s)*1.82 ± 1.67 (0.12–6.88)2.65 ± 1.55 (0.26–5.73)0.035Postoperative BCVA (logMAR)*0.06 ± 0.11 (0–0.52)0.09 ± 0.20 (0–0.70)0.431Postoperative IOP (mmHg)†14.46 ± 2.24 (10–20)15.46 ± 2.34 (11–20)0.129Values are presented as mean ± standard deviation (range). EPT was measured as EPT in the Veritas group, cumulative dissipated energy in the Centurion group; these are device-specific proprietary metrics, and the comparison should be interpreted as an indirect estimation rather than a direct quantitative measure of ultrasound energy. Values of BCVA are converted to logMAR.EPT = effective phacoemulsification time; BCVA = best-corrected visual acuity; IOP, intraocular pressure.*Mann-Whitney U-test;†Independent t-test. EPT and postoperative outcomes of moderate cataract group Values are presented as mean ± standard deviation (range). EPT was measured as EPT in the Veritas group, cumulative dissipated energy in the Centurion group; these are device-specific proprietary metrics, and the comparison should be interpreted as an indirect estimation rather than a direct quantitative measure of ultrasound energy. Values of BCVA are converted to logMAR. EPT = effective phacoemulsification time; BCVA = best-corrected visual acuity; IOP, intraocular pressure. Mann-Whitney U-test; Independent t-test. In the moderate cataract group, three cases from the Centurion group were excluded from the ECC analysis; one case due to low ECC related to previous anterior chamber lens implantation surgery for myopia correction, and two cases due to the absence of a specular microscopy exam at the 1-month follow-up. Table 5 presents the ECC changes in the moderate cataract group. There were no significant differences between the two groups in both preoperative and postoperative ECC. Although the percentage and delta values of ECC loss were lower in the Veritas group compared to the Centurion group, these differences were not statistically significant in either calculation (p = 0.437 and p = 0.351, respectively). No significant differences were observed in preoperative or postoperative CCT between the two groups. Table 5ECC and CCT changes in the moderate cataract groupVariableVeritas (n = 26)Centurion (n = 23)p-valuePreoperative ECC (cells/mm2)*2,751.96 ± 394.14 (1,866 to 3,559)2,803.57 ± 305.82 (2,268 to 3,390)0.609Postoperative ECC (cells/mm2)*2,615.50 ± 537.59 (1,751 to 4,016)2,564.70 ± 421.42 (1,852 to 3,891)0.713ECC loss (%)†4.58 ± 16.73 (−44.98 to 26.33)7.71 ± 17.04 (−35.39 to 34.63)0.437ECC loss (Δ)†136.46 ± 465.11 (−1,246 to 855)238.87 ± 478.03 (−1,017 to 981)0.351Preoperative CCT (μm)*553.77 ± 36.18 (487 to 607)570.71 ± 28.37 (490 to 611)0.076Postoperative CCT (μm)*557.62 ± 35.92 (498 to 625)576.33 ± 39.76 (501 to 632)0.095Values are presented as mean ± standard deviation (range).ECC = endothelial cell count; CCT = central corneal thickness.*Independent t-test;†Mann-Whitney U-test. ECC and CCT changes in the moderate cataract group Values are presented as mean ± standard deviation (range). ECC = endothelial cell count; CCT = central corneal thickness. Independent t-test; Mann-Whitney U-test. In the hard cataract group (Table 6), EPT was significantly lower than CDE (p = 0.009). Postoperative BCVA showed better outcomes in the Centurion group, which may be attributed to better preoperative PAM, with no significant differences between the two groups (p = 0.079). Postoperative IOP showed no significant differences between the two groups (p = 0.980). Table 6EPT and postoperative outcomes of hard cataract groupVariableVeritas (n = 17)Centurion (n = 21)p-valueEPT (%·s)*3.52 ± 2.85 (0.68–10.93)6.03 ± 3.03 (0.24–11.66)0.009Postoperative BCVA (logMAR)*0.19 ± 0.21 (0–0.70)0.09 ± 0.14 (0–0.40)0.079Postoperative IOP (mmHg)†13.88 ± 2.70 (9–20)13.90 ± 2.67 (9–19)0.980Values are presented as mean ± standard deviation (range). EPT was measured as EPT in the Veritas group, cumulative dissipated energy in the Centurion group; these are device-specific proprietary metrics, and the comparison should be interpreted as an indirect estimation rather than a direct quantitative measure of ultrasound energy. Values of BCVA are converted to logMAR.EPT = effective phacoemulsification time; BCVA = best-corrected visual acuity; IOP = intraocular pressure.*Mann-Whitney U-test;†Independent t-test. EPT and postoperative outcomes of hard cataract group Values are presented as mean ± standard deviation (range). EPT was measured as EPT in the Veritas group, cumulative dissipated energy in the Centurion group; these are device-specific proprietary metrics, and the comparison should be interpreted as an indirect estimation rather than a direct quantitative measure of ultrasound energy. Values of BCVA are converted to logMAR. EPT = effective phacoemulsification time; BCVA = best-corrected visual acuity; IOP = intraocular pressure. Mann-Whitney U-test; Independent t-test. For ECC analysis in the hard cataract group, one case from the Veritas group was excluded due to poor-quality specular microscopy imaging resulting from mild guttata (Table 7). Preoperative and postoperative ECC values were relatively similar between the two groups. While ECC loss was lower in the Veritas group, neither the percentage nor delta calculations showed statistical significance (p = 0.988). When comparing moderate versus hard cataract groups within the same machine, ECC loss was greater in the hard cataract group using the Veritas Vision System, while the reverse was observed in the Centurion group. Table 7ECC and CCT changes in the hard cataract groupVariableVeritas (n = 16)Centurion (n = 21)p-valuePreoperative ECC (cells/mm2)*2,648.75 ± 552.74 (1,653 to 3,623)2,694.29 ± 468.67 (1,923 to 3,623)0.793Postoperative ECC (cells/mm2)*2,474.00 ± 438.01 (1,661 to 3,257)2,460.81 ± 621.00 (1,041 to 3,846)0.940ECC loss (%)†4.99 ± 14.56 (−28.00 to 25.26)7.26 ± 22.53 (−39.60 to 65.96)0.988ECC loss (Δ)†174.75 ± 405.01 (−651 to 891)233.48 ± 640.56 (−1,091 to 2,017)0.988Preoperative CCT (μm)*536.93 ± 33.22 (487 to 590)551.81 ± 43.06 (478 to 633)0.272Postoperative CCT (μm)*553.43 ± 34.67 (495 to 619)555.10 ± 38.65 (479 to 630)0.898Values are presented as mean ± standard deviation (range).ECC = endothelial cell count; CCT = central corneal thickness.*Independent t-test;†Mann-Whitney U-test. ECC and CCT changes in the hard cataract group Values are presented as mean ± standard deviation (range). ECC = endothelial cell count; CCT = central corneal thickness. Independent t-test; Mann-Whitney U-test. There were no significant differences in preoperative and postoperative CCT between the two groups. No intraoperative complications, such as posterior capsular rupture, or postoperative complications like wound leaks or significant corneal edema that could impact visual acuity, were observed in any case. Discussion In our study, the Veritas system demonstrated significantly lower EPT (measured as EPT in the Veritas group and as CDE in the Centurion group) in both moderate and hard cataract groups. There were no significant differences in postoperative visual acuity or ECC changes between the two systems in both the moderate and hard cataract groups. Postoperative CCT also showed no significant differences between the two machines in both groups, with IOP remaining within the normal range. The lower EPT observed with the Veritas Vision System in the hard cataract group suggests it may exert less stress on the cornea in such cases. However, since the energy used during phacoemulsification is often associated with ECL or visual impairment due to corneal edema, the lack of significant differences in postoperative outcomes between the two systems indicates that both provide comparably safe and effective surgical outcomes [6]. With intrepid balanced tip and OZil torsional technology, the Centurion Vision System is known to enable efficient phacoemulsification with reduced ultrasound energy [7]. Additionally, the new active fluidics mechanism of the Centurion Vision System allows surgeons to operate using high vacuum, reducing the EPT [7]. The Veritas Vision System follows a workflow similar to the WhiteStar Signature Pro System and utilizes ultrasound technology that combines longitudinal and transverse energy. It also features improved fluidics, including hybrid fluidics technology for enhanced chamber stability, dual-durometer tubing for enhanced flexibility and surge protection, as well as advanced infusion for increased irrigation pressure [5]. Several studies have compared the surgical outcomes of phacoemulsification systems from different manufacturers. A prospective study by Atas et al. [6] demonstrated that the WhiteStar Signature system with Ellips FX handpiece, which combines longitudinal and transverse energy, resulted in comparable ECL to the Infiniti Vision System with OZil handpiece, which employs torsional energy, in groups with similar nuclear sclerosis grades. Similarly, Assaf and Roshdy [8] reported that one month postoperatively, there were no significant differences in ECL when comparing the WhiteStar system with Ellips FX to the Infiniti system with OZil. Additionally, Noh and Jung [9] demonstrated that the Stellaris Vision System (Bausch & Lomb), using longitudinal power, showed higher efficiency for hard cataracts and induced less ECL than the Infiniti Vision System with OZil handpiece. However, comparisons between newer-generation phacoemulsification systems from different manufacturers remain limited. Although EPT and CDE are proprietary metrics of two different manufacturers, both are derived from the same underlying variables (AVG and UST) and expressed in the same unit (%·s). The coefficient 0.4 in CDE is a physical correction applied only to the torsional component, whereas the factor 0.01 in EPT is simply an arithmetic step for converting the percentage (0%–100%) to a dimensionless decimal, not a comparable physical correction. Because the Centurion system predominantly operates in torsional mode, the 0.4 correction tends to reduce the reported CDE below the raw AVG × UST value. Therefore, our finding that Veritas EPT was lower than Centurion CDE likely represents a conservative reflection of the underlying energy difference between the two platforms, rather than an overestimation. Nevertheless, since EPT and CDE remain device-specific proprietary metrics, this comparison should be interpreted as an indirect estimation rather than a direct quantitative measure of ultrasound energy efficiency between the two systems. A plausible explanation for the shorter effective phaco time observed with the Veritas system in hard cataracts may lie in its combination of the Ellips FX handpiece and the WhiteStar technology. The Ellips FX handpiece enhances cutting efficiency while reducing repulsion of nuclear material, and the WhiteStar ultra-pulse technology enables rapid modulation of ultrasound energy with short on-off cycles, maintaining cutting efficiency and follow-ability while reducing unnecessary energy delivery [10]. By turning off rapidly, it may also make more efficient use of cavitational energy than continuous ultrasound, thereby allowing effective nuclear removal with less cumulative energy. These design features may account for the shorter EPT observed with the Veritas Vision System without significantly compromising postoperative visual acuity or ECC outcomes. This study has several limitations. First, it was retrospective in nature. Second, we did not measure the amount of balanced-salt solution used for irrigation, the duration of irrigation/aspiration, and total surgery time, all of which may influence surgical outcomes. In addition, endothelial morphological parameters such as hexagonality and coefficient of variation were not included in this study, which may limit a comprehensive assessment of endothelial cell status. Third, we compared the two systems based on different platforms from different manufacturers, which complicates direct comparisons. As mentioned above, although the two devices were manufactured by different companies, we considered it meaningful to compare the parameters, as the surgeries were performed using settings and handpieces optimized for each device. Fourth, a wide range of IOLs were implanted, including monofocal, enhanced monofocal, extended depth of focus, and multifocal IOLs from various manufacturers, which may have affected visual outcomes. Fifth, cataract severity was classified based solely on NO according to the Lens Opacities Classification System III grading, without considering other components such as CO and posterior subcapsular opacity. Although NO is most closely associated with lens hardness and phacoemulsification energy, these additional opacity types may influence postoperative visual outcomes. Lastly, in some cases, ECC loss was recorded as less than 0%, suggesting possible measurement errors during ECC assessment, although each measurement was repeatedly performed by the same experienced examiner under consistent conditions. When using the same device in our study, the hard cataract group required higher ultrasound energy but did not consistently show higher ECL compared to the moderate cataract group. This finding contrasts with previous studies using the same machine, which reported significantly greater ECL in the hard cataract group compared to the moderate group, which may imply that measurement errors in our ECC assessment could have influenced the results [6,11]. However, adequate corneal protection with ophthalmic viscosurgical devices and the improved stability of modern phaco systems may have helped minimize endothelial damage, suggesting that longer phaco time does not necessarily lead to greater ECC loss when surgery is performed carefully by experienced surgeons. In conclusion, both the Veritas and the Centurion Vision System demonstrated good performance with stable surgical outcomes, and the differences in corneal ECL and postoperative visual acuity were not significant. These findings suggest that both systems are effective and safe for cataract surgery. Footnotes Conflicts of Interest None. Acknowledgements None. Funding None. Supplementary Materials Supplementary Table 1. Phacoemulsification settings in two systems References Associated Data Supplementary Materials Supplementary Table 1. Phacoemulsification settings in two systems